SCHEMBL4922804

SCHEMBL4922804

O=C(Nc1ccc(F)cc1)Nc1ccc(C(=O)c2ccccc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.66
NPC1 O15118 5/20 0.66
MEN1 O00255 5/20 0.63
KMT2A Q03164 5/20 0.63
POLB P06746 3/20 0.63
TDP1 Q9NUW8 1/20 0.63
ALDH1A1 P00352 3/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
SMN1; SMN2 Q16637 4/20 0.60
HTT P42858 3/20 0.60
MAPT P10636 3/20 0.60
MAPK1 P28482 1/20 0.60
SIRT1 Q96EB6 1/20 0.58
FFAR1 O14842 1/20 0.57
MAPK13 O15264 1/20 0.56
MAPK12 P53778 1/20 0.56
MAPK11 Q15759 1/20 0.56
MAPK14 Q16539 1/20 0.56
TAAR1 Q96RJ0 2/20 0.56
HPGD P15428 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17831070 0.89 RAB9A (0.71) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL11056635 0.87 SMN1; SMN2 (0.74) RAB9ANPC1MEN1KMT2APOLB
Benzene SCHEMBL27709388 0.84 ALDH1A1 (0.70) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL7940606 0.84 ALDH1A1 (0.70) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL27483853 0.84 ALDH1A1 (0.70) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL251921 0.84 ALDH1A1 (0.70) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL17068941 0.84 ALDH1A1 (0.70) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL4922979 0.83 MITF (0.76) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL7373156 0.82 ALDH1A1 (0.67) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL3070329 0.82 KMT2A (0.76) RAB9ANPC1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R RAB9A 3359/4885NPC1 148/4885MEN1 4843/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R RAB9A 3359/4885NPC1 148/4885MEN1 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.